Moderna COVID-19 vaccine appears to clear safety hurdle in mouse study


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ moderna-covid19-vaccine-safety-hurdle-mouse-study
The authors said that they have submitted the work to a top-tier journal

A series of studies conducted in mice of Moderna’s COVID-19 vaccine research lent some assurance that it may not hike the risk of more severe disease, and that one dose may provide protection against the novel coronavirus, according to primary data.

Previous studies on a vaccine for SARS – a close cousin to the new virus that causes COVID-19 – show that the vaccines against this type of virus might have the unwanted effect of causing more severe disease when the vaccinated person is later exposed to the pathogen, especially in individuals who do not develop an adequately strong immune response.

Scientists have seen this risk as an obstacle to clear before the vaccines can be safely tested in thousands of healthy people.

While the data published by the US National Institutes of Allergy and Infectious Disease (NIAID) and Moderna offered some confirmation, the studies do not fully answer the question.

“This is the barest beginning of preliminary information,” said Dr. Gregory Poland, an immunologist and vaccine researcher at the Mayo Clinic who has seen the paper, which has yet to undergo peer-review.

Poland said the papers were incomplete, disorganized and the number of animals tested were too small.

The authors said that they have submitted the work to a top-tier journal. Moderna’s vaccine is in mid-stage testing in healthy individuals Moderna said on Thursday that it plans to start final-stage trials by enrolling 30,000 people in July.

In the animal studies, mice were given one or two shots of a variety of doses of Moderna’s vaccine, including doses considered to be not strong enough to induce a protective immune response. They then exposed the mice to the virus.

Subsequent analysis suggest that “sub-protective” I'mmune responses do not become the cause of what is known as vaccine-associated enhanced respiratory disease, a vulnerability to more severe disease in the lungs.

“Subprotective doses did not prime mice for enhanced immunopathology following (exposure),” Dr. Barney Graham of the Vaccine Research Center at NIAID and colleagues wrote in the manuscript, posted on the bioRxiv website.

Further testing showed that the vaccine induces antibody responses to stop the virus from infecting cells.

The vaccine was also seen give protection against infection by the coronavirus in the lungs and noses without a trace of toxic effects, the team wrote.

They noticed that the mice which received just one dose before exposure to the virus seven weeks later were seen to be “completely protected against lung viral replication,” suggesting that a single dose of the vaccination prevented the virus from replicating in the lungs.

“At first glance, it looks promising in inducing neutralizing antibody protection in mice,” Dr. Peter Hotez, a researcher at Baylor College of Medicine said in an email. He had not reviewed the paper in detail.

Poland, who was not involved in the research, said the paper leaves out “important parameters” that could be helpful for the scientists in judging the work.
“The results, such as they are presented, provide interesting data that are reassuring … This needs to be replicated and it needs to be peer-reviewed,” he said.

Tags : #Moderna #COVID-19

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026